Led by these limitations, a major paradigm shift in the management of LC therapy has occurred as innovative researchers aimed to develop newer drugs/delivery systems to specifically target over-expressed factors such as cluster determinant 44 receptor (CD44), EGFR (epidermal growth factor receptor), folate receptor and so on. Here, EGFR is linked to laryngotracheoesophageal cleft.